- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Nissen Outlines New Treatments in Cardiovascular Medicine
Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Transcript
What do you believe will be the next breakthroughs in cardiovascular medicine?
Well there will be a trial presented at this meeting; the topline results have been announced in a press release. It's the use of a pure anti-inflammatory drug, known as canakinumab, and the trial is CANTOS. It's going to be presented by Paul Ridker, MD. Since the data are still embargoed, what I can say here is that the topline results are that the trial met its pre-specificed endpoints.
But watch this space. Because here is a drug that doesn't lower low-density lipoprotein cholesterol, doesn't raise high-density lipoprotein, doesn't loewr triglycerides, but based upon the press release, it reduces major cardiovascular events. A pure anti-inflammatory strategy. It's fascinating. It's a new window opening on another approach to treatment. And we're very excited about the results.
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
